P53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

Ellen J. Schlette, Joan Admirand, William Wierda, Lynne Abruzzo, Katherine I. Lin, Susan O'Brien, Susan Lerner, Michael J. Keating, Constantine Tam

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Although chromosome 17p abnormalities and TP53 mutations have been reported as poor prognostic indicators in chronic lymphocytic leukemia (CLL), the impact of aberrant p53 expression as assessed by immunohistochemistry (p53-IHC) has not been defined in patients with CLL treated with chemoimmunotherapy, particularly in the context of other novel markers such as ZAP-70 expression and IgVH mutation status (IgVH MS). We assessed p53-IHC in 222 bone marrow (BM) specimens from patients with CLL enrolled in a phase II trial with fludarabine, cyclophosphamide, and rituximab (FCR). ZAP70 expression and IgVH MS were assessed in 208 and 108 patients, respectively. One hundred sixty-eight patients had concurrent classical cytogenetic analysis. p53-IHC correlated with abnormal karyotype (p = 0.002) and adversely affected overall survival independent of ZAP70 expression and IgVH MS (p < 0.001). Patients with p53-IHC(+)CLL were less likely to achieve complete remission, but patients who did achieve complete remission showed a durable response. In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR.

Original languageEnglish (US)
Pages (from-to)1597-1605
Number of pages9
JournalLeukemia and Lymphoma
Volume50
Issue number10
DOIs
StatePublished - Nov 11 2009

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunotherapy
Immunohistochemistry
Survival
Mutation
Cyclophosphamide
Abnormal Karyotype
Cytogenetic Analysis
Chromosome Aberrations
Bone Marrow

Keywords

  • Chronic lymphocytic leukemia
  • P53
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

P53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. / Schlette, Ellen J.; Admirand, Joan; Wierda, William; Abruzzo, Lynne; Lin, Katherine I.; O'Brien, Susan; Lerner, Susan; Keating, Michael J.; Tam, Constantine.

In: Leukemia and Lymphoma, Vol. 50, No. 10, 11.11.2009, p. 1597-1605.

Research output: Contribution to journalArticle

Schlette, Ellen J. ; Admirand, Joan ; Wierda, William ; Abruzzo, Lynne ; Lin, Katherine I. ; O'Brien, Susan ; Lerner, Susan ; Keating, Michael J. ; Tam, Constantine. / P53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 10. pp. 1597-1605.
@article{c9ccabdc394c465b99e18db34e0b7467,
title = "P53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy",
abstract = "Although chromosome 17p abnormalities and TP53 mutations have been reported as poor prognostic indicators in chronic lymphocytic leukemia (CLL), the impact of aberrant p53 expression as assessed by immunohistochemistry (p53-IHC) has not been defined in patients with CLL treated with chemoimmunotherapy, particularly in the context of other novel markers such as ZAP-70 expression and IgVH mutation status (IgVH MS). We assessed p53-IHC in 222 bone marrow (BM) specimens from patients with CLL enrolled in a phase II trial with fludarabine, cyclophosphamide, and rituximab (FCR). ZAP70 expression and IgVH MS were assessed in 208 and 108 patients, respectively. One hundred sixty-eight patients had concurrent classical cytogenetic analysis. p53-IHC correlated with abnormal karyotype (p = 0.002) and adversely affected overall survival independent of ZAP70 expression and IgVH MS (p < 0.001). Patients with p53-IHC(+)CLL were less likely to achieve complete remission, but patients who did achieve complete remission showed a durable response. In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR.",
keywords = "Chronic lymphocytic leukemia, P53, Prognostic factors",
author = "Schlette, {Ellen J.} and Joan Admirand and William Wierda and Lynne Abruzzo and Lin, {Katherine I.} and Susan O'Brien and Susan Lerner and Keating, {Michael J.} and Constantine Tam",
year = "2009",
month = "11",
day = "11",
doi = "10.1080/10428190903165241",
language = "English (US)",
volume = "50",
pages = "1597--1605",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - P53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

AU - Schlette, Ellen J.

AU - Admirand, Joan

AU - Wierda, William

AU - Abruzzo, Lynne

AU - Lin, Katherine I.

AU - O'Brien, Susan

AU - Lerner, Susan

AU - Keating, Michael J.

AU - Tam, Constantine

PY - 2009/11/11

Y1 - 2009/11/11

N2 - Although chromosome 17p abnormalities and TP53 mutations have been reported as poor prognostic indicators in chronic lymphocytic leukemia (CLL), the impact of aberrant p53 expression as assessed by immunohistochemistry (p53-IHC) has not been defined in patients with CLL treated with chemoimmunotherapy, particularly in the context of other novel markers such as ZAP-70 expression and IgVH mutation status (IgVH MS). We assessed p53-IHC in 222 bone marrow (BM) specimens from patients with CLL enrolled in a phase II trial with fludarabine, cyclophosphamide, and rituximab (FCR). ZAP70 expression and IgVH MS were assessed in 208 and 108 patients, respectively. One hundred sixty-eight patients had concurrent classical cytogenetic analysis. p53-IHC correlated with abnormal karyotype (p = 0.002) and adversely affected overall survival independent of ZAP70 expression and IgVH MS (p < 0.001). Patients with p53-IHC(+)CLL were less likely to achieve complete remission, but patients who did achieve complete remission showed a durable response. In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR.

AB - Although chromosome 17p abnormalities and TP53 mutations have been reported as poor prognostic indicators in chronic lymphocytic leukemia (CLL), the impact of aberrant p53 expression as assessed by immunohistochemistry (p53-IHC) has not been defined in patients with CLL treated with chemoimmunotherapy, particularly in the context of other novel markers such as ZAP-70 expression and IgVH mutation status (IgVH MS). We assessed p53-IHC in 222 bone marrow (BM) specimens from patients with CLL enrolled in a phase II trial with fludarabine, cyclophosphamide, and rituximab (FCR). ZAP70 expression and IgVH MS were assessed in 208 and 108 patients, respectively. One hundred sixty-eight patients had concurrent classical cytogenetic analysis. p53-IHC correlated with abnormal karyotype (p = 0.002) and adversely affected overall survival independent of ZAP70 expression and IgVH MS (p < 0.001). Patients with p53-IHC(+)CLL were less likely to achieve complete remission, but patients who did achieve complete remission showed a durable response. In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR.

KW - Chronic lymphocytic leukemia

KW - P53

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=70350784064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350784064&partnerID=8YFLogxK

U2 - 10.1080/10428190903165241

DO - 10.1080/10428190903165241

M3 - Article

VL - 50

SP - 1597

EP - 1605

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -